Johanna Rehnberg1,2, Adina Symreng3, Jonas F Ludvigsson4,5,6,7, Louise Emilsson8,5,9,10. 1. Department of Nephrology and Centre for Clinical Research, County Council of Värmland, Central Hospital Karlstad, Karlstad, Sweden. 2. School of Medical Science, University of Örebro, Örebro, Sweden. 3. Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. 4. Department of Pediatrics, Örebro University Hospital, Örebro, Sweden. 5. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 6. Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, New York. 7. Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, United Kingdom. 8. School of Medical Science, University of Örebro, Örebro, Sweden louise.emilsson@medisin.uio.no. 9. Årjäng Health Care Center and Centre for Clinical Research, County Council of Värmland, Värmland, Sweden. 10. Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.
Abstract
BACKGROUND: Case reports suggest an association between inflammatory bowel disease, a chronic autoimmune condition linked to increased circulating IgA levels, and IgA nephropathy, the most common form of primary GN and a leading cause of ESKD. METHODS: In a Swedish population-based cohort study, we compared 3963 biopsy-verified IgA nephropathy patients with 19,978 matched controls between 1974 and 2011, following up participants until 2015. Inflammatory bowel disease data and ESKD status were obtained through national medical registers. We applied Cox regression to estimate hazard ratios (HRs) for future inflammatory bowel disease in IgA nephropathy and conditional logistic regression to assess risk of earlier inflammatory bowel disease in IgA nephropathy. We also explored whether inflammatory bowel disease affects development of ESKD in IgA nephropathy. RESULTS: During a median follow-up of 12.6 years, 196 (4.95%) patients with IgA nephropathy and 330 (1.65%) matched controls developed inflammatory bowel disease (adjusted HR, 3.29; 95% confidence interval [95% CI], 2.73 to 3.96). Inflammatory bowel disease also was more common before a confirmed IgA nephropathy diagnosis. Some 103 (2.53%) IgA nephropathy patients had an earlier inflammatory bowel disease diagnosis compared with 220 (1.09%) controls (odds ratio [OR], 2.37; 95% CI, 1.87 to 3.01). Both logistic regression (OR, 2.60; 95% CI, 2.02 to 3.35) and time-varying Cox regression (HR, 1.84; 95% CI, 1.33 to 2.55) demonstrated that inflammatory bowel disease was associated with increased ESKD risk in patients with IgA nephropathy. CONCLUSIONS: Patients with IgA nephropathy have an increased risk of inflammatory bowel disease both before and after their nephropathy diagnosis. In addition, among patients with IgA nephropathy, comorbid inflammatory bowel disease elevates the risk of progression to ESKD.
BACKGROUND: Case reports suggest an association between inflammatory bowel disease, a chronic autoimmune condition linked to increased circulating IgA levels, and IgA nephropathy, the most common form of primary GN and a leading cause of ESKD. METHODS: In a Swedish population-based cohort study, we compared 3963 biopsy-verified IgA nephropathy patients with 19,978 matched controls between 1974 and 2011, following up participants until 2015. Inflammatory bowel disease data and ESKD status were obtained through national medical registers. We applied Cox regression to estimate hazard ratios (HRs) for future inflammatory bowel disease in IgA nephropathy and conditional logistic regression to assess risk of earlier inflammatory bowel disease in IgA nephropathy. We also explored whether inflammatory bowel disease affects development of ESKD in IgA nephropathy. RESULTS: During a median follow-up of 12.6 years, 196 (4.95%) patients with IgA nephropathy and 330 (1.65%) matched controls developed inflammatory bowel disease (adjusted HR, 3.29; 95% confidence interval [95% CI], 2.73 to 3.96). Inflammatory bowel disease also was more common before a confirmed IgA nephropathy diagnosis. Some 103 (2.53%) IgA nephropathy patients had an earlier inflammatory bowel disease diagnosis compared with 220 (1.09%) controls (odds ratio [OR], 2.37; 95% CI, 1.87 to 3.01). Both logistic regression (OR, 2.60; 95% CI, 2.02 to 3.35) and time-varying Cox regression (HR, 1.84; 95% CI, 1.33 to 2.55) demonstrated that inflammatory bowel disease was associated with increased ESKD risk in patients with IgA nephropathy. CONCLUSIONS: Patients with IgA nephropathy have an increased risk of inflammatory bowel disease both before and after their nephropathy diagnosis. In addition, among patients with IgA nephropathy, comorbid inflammatory bowel disease elevates the risk of progression to ESKD.
Authors: R J Wyatt; B A Julian; R W Baehler; C C Stafford; R G McMorrow; T Ferguson; E Jackson; S Y Woodford; P M Miller; S Kritchevsky Journal: J Am Soc Nephrol Date: 1998-05 Impact factor: 10.121
Authors: Ravy K Vajravelu; Lawrence Copelovitch; Mark T Osterman; Frank I Scott; Ronac Mamtani; James D Lewis; Michelle R Denburg Journal: Clin Gastroenterol Hepatol Date: 2019-11-01 Impact factor: 11.382
Authors: Simon Jarrick; Sigrid Lundberg; Adina Welander; C Michael Fored; Jonas F Ludvigsson Journal: Clin Epidemiol Date: 2017-01-31 Impact factor: 4.790
Authors: Jussi Pohjonen; Rakel Nurmi; Martti Metso; Pia Oksanen; Heini Huhtala; Ilkka Pörsti; Jukka Mustonen; Katri Kaukinen; Satu Mäkelä Journal: Clin Kidney J Date: 2019-02-28